Abstract
Background: Data suggest that esophageal cancers staged as T4 by EUS do not benefit from resection. However, these studies were performed prior to the widespread use of preoperative neoadjuvant chemoradiation. We investigated whether baseline EUS predicts CR (no histological evidence for residual tumor at surgical resection) to neoadjuvant therapy. Methods: Pts with esophageal ca (regardless of tissue type) underwent EUS staging. Those staged as T2-T4 were then treated with 5FU/cisplatin/radiation, followed by resection. EUS results were compared with pathologic staging of the resected specimen (chi-square). Results: 42 pts were treated between 2/93 and 9/97 (30 adeno, 12 squamous). All Tumor Tissue Types EUS T stage No. Pts No. CR % CR p-value 2 5 3 60 0.44 (NS) 3 30 11 37 4 7 4 57 EUS N stage No. Pts No. CR % CR p-value 0 16 7 44 0.99 (NS) 1 25 11 44 Adenocarcinoma EUS T stage No. Pts No. CR % CR p-value 2 24 3 75 0.37 (NS) 3 24 9 38 4 2 1 50 EUS N stage No. Pts No. CR % CR p-value 0 11 4 38 0.47 (NS) 1 18 9 50 Conclusion: EUS staging of esophageal carcinoma does not predict CR after subsequent neoadjuvant chemoradiation and resection. Whether pre-treatment EUS stage correlates with survival will require longer follow-up.
| Original language | English (US) |
|---|---|
| Journal | Gastrointestinal Endoscopy |
| Volume | 47 |
| Issue number | 4 |
| State | Published - Dec 1 1998 |
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Gastroenterology
